Meet the Panelists of Digital Health Innovations – What They Are, How to Protect Them, and Commercialization Strategies
February 23, 2021
Kathryn Bowsher is a commercial strategist with deep expertise in go-to-market and adoption of new solutions throughout healthcare. Starting with novel drugs and devices and evolving into digital health and innovative care models, Kathryn has driven the success of 40+ products and initiatives, spanning a wide range of therapeutic areas, sites of care and business models, the world over. She leverages a rare, holistic understanding of the complex health care ecosystem to help organizations such as Amgen, Stanford Health, Raptor and Bayer achieve transformative change.
Today she is the Managing Director of Act One Healthcare, serves on the board of Pocket Naloxone Corp and Red Team Associates, and advises Nassau Street Ventures. Previously Kathryn was President, CEO and Director of PurThread Technologies, founder and CEO of a commercial strategy consulting group, VP of Marketing at Somnus Medical and Director of Global Marketing for Baxter’s largest product line. She began her work with new solutions at Goldman Sachs & Co. Kathryn holds an M.B.A. from the Stanford University Graduate School of Business. She earned an A.B cum laude from Princeton University.
Peter M. Fleischut, MD, is Senior Vice President and Chief Transformation Officer for NewYork-Presbyterian. In this role, he leads NYP’s enterprise EMR integration, pharmacy operations, innovation and transformation. Dr. Fleischut is also responsible for the development of the NYP OnDemand suite of digital health services and the implementation of clinical operations for the new David H. Koch Center at NewYork-Presbyterian/Weill Cornell.
A graduate of Jefferson Medical College and the Wharton Program for Working Professionals at the University of Pennsylvania, Dr. Fleischut joined NewYork-Presbyterian Hospital/Weill Cornell in 2006 and has held the roles of Medical Director of the Operating Rooms, Deputy Quality Patient Safety Officer, Founding Director of the Center for Perioperative Outcomes, Vice Chairman, Chief Medical Information Officer, Chief Innovation Officer and Chief Medical Operating Officer. In 2016, he was appointed Vice Chair of the Department of Anesthesiology at Weill Cornell Medical College, where he is an Assistant Professor of Anesthesiology.
Dr. Fleischut has received numerous awards and honors, including NewYork-Presbyterian’s Physician of the Year, Modern Healthcare Up and Comers, Becker’s Hospital Review 40 under 40, and the American Telehealth Association President’s Award.
Jason Novak is a Partner in Haynes and Boone’s Precision Medicine and Digital Health Practice Group, where he focuses on advising entities, both large and small, on the various legal issues that can arise with emerging technologies in the healthcare and life sciences industries. Tech and Biotech are traditionally disparate technologies that, when blended together to form many of our most exciting new technologies, bring forth a combination of unique and interrelated legal issues.
Jason has extensive experience in IP strategy and patent portfolio management, preparation and prosecution, oppositions, counseling, licensing and technology transactions, in and out-licensing, freedom-to-operate, various types of due diligence, IP training, risk recognition and management, and dispute resolution. He directs that experience to clients in various industries, particularly in the medical device, personalized/precision medicine (e.g., genomic sequencing platforms, computational genomics/bioinformatics, and molecular diagnostics), digital health, life sciences tooling, and food industries.
Prior to starting this practice, Jason was a IP Director for Thermo Fisher Scientific, where he managed worldwide IP needs in genetic sciences instrumentation and software (e.g., qPCR, dPCR, capillary electrophoresis). Jason managed large IP portfolios, a team of agents and attorneys, licensing programs, various diligence needs, various IP-related transactions, and foreign and domestics patent challenges.
Before moving into the legal industry, Jason was a research engineer for a leading food product company, where he led numerous product and process redesigns, reformulations and launches. This cross-functional role required interaction and experience with operations, finance, marketing and regulatory areas, contributing to Jason’s ability to deal with various corporate functions from both an R&D and legal perspective.
Roger Kuan is a Partner at Haynes and Boone and chair of the Precision Medicine and Digital Health Practice Group, where he counsels companies that are uniquely positioned in the convergence of the life/medical sciences and technology industries on how to successfully navigate the complexities of the intellectual property (IP), data rights and regulatory challenges they encounter.
Roger has extensive experience in IP strategy and portfolio management (utility/design patents, trademarks, copyrights, and trade dress), data rights strategy, licensing and technology transactions, freedom-to-operate clearances, enforcement, monetization, IP due diligence, and dispute resolution. His practice is focused in the life sciences sector (e.g., research tools, analytical instrumentation/software, digital therapeutics, medical devices, diagnostics, biomanufacturing equipment, etc.) with an emphasis in emerging technologies such as Precision Medicine (e.g., genomic sequencing platforms, AI/ML, computational genomics/bioinformatics, molecular diagnostics, companion diagnostics, etc.), Digital Health (e.g., mobile apps, clinical decision support, software, digital therapeutics, AI/ML Imaging Diagnostics, wearables, etc.) and 3D printing/bioprinting.
Prior to joining Haynes and Boone, Roger served as Director, IP Counsel at a multinational biotechnology company, where he managed a team to support the worldwide IP needs of the company’s life sciences tools, bioproduction/biomanufacturing, molecular diagnostics, and nucleic acid sequencing system/software platforms. Prior to finishing his law degree, he worked in the life sciences industry for several Fortune 500 pharmaceutical, medical device, and chemical companies. He has held professional positions in the R&D, sales, engineering, and regulatory affairs organizations.
Dr. Placanica is Senior Managing Director, Center for Technology Licensing at WCM. In this role, she is responsible for overseeing WCM’s activities in technology management, marketing, licensing, and outreach to support Cornell’s goals in commercializing technologies, promoting start-ups, and building partnerships.
Prior to joining WCM in 2020, Dr. Placanica held the position of Managing Director, Business Development and Licensing at Mount Sinai Innovation Partners. In this role, she was responsible for managing a team of business development professionals focused on identifying, advancing, and partnering therapeutic technologies developed at the Mount Sinai Health System and acted as deal team lead for closing complex intellectual property transactions. Dr. Placanica also was a Licensing Manager in the Office of Technology Development at Memorial Sloan Kettering Cancer Center where she focused on development and commercialization of cell and gene therapy related inventions and previously was a key member of the Cell Biology research group at Athersys, Inc in Cleveland, Ohio.
Dr. Placanica received her Ph.D. in Pharmacology from Weill Cornell Medical College where she studied the biochemical composition of gamma secretase and its role in Alzheimer’s Disease in the laboratory of Dr. Yueming Li at Memorial Sloan Kettering Cancer Center. She holds a B.A. in Biology from Cornell University where she graduated Magna Cum Laude with Distinction.
In 2013, Dr. Placanica became a Certified Licensing Professional.
More information on Weill Digital Health Series: